Clinical trial
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
NCT00081263 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00081263 |
|---|---|
| Title | Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia |
| Official title | A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or 3) |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3, Stage 0 Cervical Cancer |
| Intervention type | Drug, Other |
| Interventions | Celecoxib, Laboratory Biomarker Analysis, Placebo |
| Enrollment | 130 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2012 |
| First posted | Apr 8, 2004 |
| Last update posted | Sep 15, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: